tetano
Editor, Senior Moderator
Nat Rev Immunol
. 2024 May 2.
doi: 10.1038/s41577-024-01030-8. Online ahead of print. Opportunities and challenges for T cell-based influenza vaccines
Tim R Mosmann[SUP] 1 [/SUP], Andrew J McMichael[SUP] 2 [/SUP], Alexandre LeVert[SUP] 3 [/SUP], John W McCauley[SUP] 4 [/SUP], Jeffrey W Almond[SUP] 5 [/SUP]
Affiliations
Vaccination remains our main defence against influenza, which causes substantial annual mortality and poses a serious pandemic threat. Influenza virus evades immunity by rapidly changing its surface antigens but, even when the vaccine is well matched to the current circulating virus strains, influenza vaccines are not as effective as many other vaccines. Influenza vaccine development has traditionally focused on the induction of protective antibodies, but there is mounting evidence that T cell responses are also protective against influenza. Thus, future vaccines designed to promote both broad T cell effector functions and antibodies may provide enhanced protection. As we discuss, such vaccines present several challenges that require new strategic and economic considerations. Vaccine-induced T cells relevant to protection may reside in the lungs or lymphoid tissues, requiring more invasive assays to assess the immunogenicity of vaccine candidates. T cell functions may contain and resolve infection rather than completely prevent infection and early illness, requiring vaccine effectiveness to be assessed based on the prevention of severe disease and death rather than symptomatic infection. It can be complex and costly to measure T cell responses and infrequent clinical outcomes, and thus innovations in clinical trial design are needed for economic reasons. Nevertheless, the goal of more effective influenza vaccines justifies renewed and intensive efforts.
. 2024 May 2.
doi: 10.1038/s41577-024-01030-8. Online ahead of print. Opportunities and challenges for T cell-based influenza vaccines
Tim R Mosmann[SUP] 1 [/SUP], Andrew J McMichael[SUP] 2 [/SUP], Alexandre LeVert[SUP] 3 [/SUP], John W McCauley[SUP] 4 [/SUP], Jeffrey W Almond[SUP] 5 [/SUP]
Affiliations
- PMID: 38698082
- DOI: 10.1038/s41577-024-01030-8
Vaccination remains our main defence against influenza, which causes substantial annual mortality and poses a serious pandemic threat. Influenza virus evades immunity by rapidly changing its surface antigens but, even when the vaccine is well matched to the current circulating virus strains, influenza vaccines are not as effective as many other vaccines. Influenza vaccine development has traditionally focused on the induction of protective antibodies, but there is mounting evidence that T cell responses are also protective against influenza. Thus, future vaccines designed to promote both broad T cell effector functions and antibodies may provide enhanced protection. As we discuss, such vaccines present several challenges that require new strategic and economic considerations. Vaccine-induced T cells relevant to protection may reside in the lungs or lymphoid tissues, requiring more invasive assays to assess the immunogenicity of vaccine candidates. T cell functions may contain and resolve infection rather than completely prevent infection and early illness, requiring vaccine effectiveness to be assessed based on the prevention of severe disease and death rather than symptomatic infection. It can be complex and costly to measure T cell responses and infrequent clinical outcomes, and thus innovations in clinical trial design are needed for economic reasons. Nevertheless, the goal of more effective influenza vaccines justifies renewed and intensive efforts.